Featured Press Releases

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

  • 26 Jan 2025

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, and...

Redefining Pharmaceutical Market Analytics and Insights: PharmaScroll

Redefining Pharmaceutical Market Analytics and Insights: PharmaScroll

Lykos Therapeutics Provides Update on FDA Advisory Committee Meeting for Investigational MDMA-Assisted PTSD Therapy

Lykos Therapeutics Provides Update on FDA Advisory Committee Meeting for Investigational MDMA-Assisted PTSD Therapy

At the PHPN 2025 Symposium, Corsair Pharma will present new data on its proprietary transdermal system for Treprostinil prodrug

At the PHPN 2025 Symposium, Corsair Pharma will present new data on its proprietary transdermal system for Treprostinil prodrug

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

  • Johnson & Johnson
  • 25 Jun 2026
StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

  • StatLab Medical Products
  • 25 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

  • Zeta Surgical
  • 23 Jun 2026
Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

  • Upsher-Smith Laboratories, LLC
  • 23 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.